Business Wire

Medicago and GSK Announce Positive Phase 3 Efficacy and Safety Results for Adjuvanted Plant-Based COVID-19 Vaccine Candidate

Share

Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) today announce positive efficacy and safety results from the global Phase 3 placebo-controlled efficacy study of Medicago’s plant-based COVID-19 vaccine candidate in combination with GSK’s pandemic adjuvant, conducted in over 24,000 subjects, adults 18 years and above, across six countries.

Vaccine efficacy was demonstrated in an environment dominated by SARS-CoV-2 variants, unlike most published Phase 3 efficacy trials for currently licensed COVID-19 vaccines that were conducted when only the ancestral virus was circulating, making direct comparisons impossible. The overall vaccine efficacy rate against all variants of SARS-CoV-2 was 71% (95% Confidence Interval: CI 58.7, 80.0; Per Protocol Analysis: PP). The corresponding number for people with an initial seronegative status indicating no previous exposure to COVID-19 was 75.6% (95% CI: 64.2-83.7; PP). The vaccine candidate demonstrated efficacy of 75.3% (95% CI: 52.8, 87.9; PP) against COVID-19 of any severity for the globally dominant Delta variant. Efficacy was 88.6% (95% CI: 74.6, 95.6; PP) against the Gamma variant. Although only a small number of severe cases occurred in this study, none occurred in the vaccinated group. No cases of the Alpha, Lambda and Mu variants were observed in the vaccinated group while 12 cases were observed in the placebo group. The Omicron variant was not circulating during the study.

During the study, no related serious adverse events were reported and reactogenicity was generally mild to moderate and transient; symptoms lasting on average only 1 to 3 days. To date, the Phase 3 results have confirmed the safety profile is consistent with Phase 2 results. The frequency of mild fever was low (<10%), even after the second dose.

Full results of the Phase 3 study will be released in a peer-reviewed publication as soon as possible.

Based on these results, Medicago will imminently seek regulatory approval from Health Canada as part of its rolling submission. The vaccine candidate is not approved yet by any regulatory authorities.

“This is an incredible moment for Medicago and for novel vaccine platforms. The results of our clinical trials show the power of plant-based vaccine manufacturing technology. If approved, we will be contributing to the world’s fight against the COVID-19 pandemic with the world’s first plant-based vaccine for use in humans,” said Takashi Nagao, CEO and President at Medicago. “I want to thank everyone who participated in our clinical trials, our collaborators at clinical trial sites, our partners at GSK, the Government of Canada and Government of Quebec, Mitsubishi Tanabe Pharma Corporation, and all of our employees and our shareholders, for their commitment to advancing vaccine science when the world needs it.”

Thomas Breuer, GSK’s global COVID-19 adjuvanted vaccines lead and Chief Global Health Officer, said, “These are encouraging results given data were obtained in an environment with no ancestral virus circulating. The global COVID-19 pandemic is continuing to show new facets with the current dominance of the Delta variant, upcoming Omicron, and other variants likely to follow. The combination of GSK’s established pandemic adjuvant with Medicago’s plant-based vaccine technology has significant potential to be an effective, refrigerator-stable option to help protect people against SARS-CoV-2.”

Medicago has been developing its plant-based technology for the past 20 years, using unique technology to produce Virus-Like Particles (VLP) for its protein vaccines. VLPs are designed to mimic the native structure of viruses, allowing them to be easily recognized by the immune system. Because the VLPs lack core genetic material, they are non-infectious and unable to replicate. VLP vaccines developed by other technologies, have traditionally been used worldwide for more than 30 years.

“I am pleased to see our vaccine candidate moving forward and bringing to the world the first plant-based vaccine against COVID-19, diversifying the pool of vaccines available to help improve public health and protect more people,” said Yosuke Kimura, Chief Scientific Officer at Medicago.

Medicago has initiated the regulatory filing process for the adjuvanted plant-based COVID-19 vaccine candidate with FDA and MHRA. Preliminary discussion is underway with the WHO for preparation of the submission. Medicago has also initiated Phase 1/2 trial in Japan where it plans to submit for regulatory approval in combination with the Phase 2/3 global study results next spring.

About the Phase 2/3 study

The Phase 2/3 study has a multi-portion design to confirm that the chosen formulation and dosing regimen of the vaccine candidate (two doses of 3.75 µg of antigen combined with GSK's pandemic adjuvant given 21 days apart) has an acceptable vaccine profile in healthy adults 18-64 years of age, elderly subjects aged 65 and over and adults with comorbidities.

The Phase 2 portion of the trial was a randomized, observer-blind, placebo-controlled study to evaluate the safety and immunogenicity of the adjuvanted recombinant COVID-19 plant-based vaccine candidate in subjects aged 18 and above. It was conducted in multiples sites in Canada and the United States in a population composed of healthy adults (18-64y), elderly adults (over 65y) and adults with comorbidities. Each age group enrolled up to 306 subjects randomized 5:1 to receive the adjuvanted vaccine candidate: placebo and with 2:1 stratification in older adults (65-74 and ≥75). All subjects are being followed for a period of 12 months after the last vaccination for assessment of safety and the durability of the immune responses which will be the final analysis.

The Phase 3 portion of the trial was launched on March 16th, 2021, and was an event-driven, randomized, observer-blinded, crossover placebo-controlled design that evaluated the efficacy and safety of the vaccine candidate formulation, compared to placebo, in over 24,000 subjects across Canada, United States, United Kingdom, Mexico, Argentina, and Brazil.

The data communicated are Per-Protocol, meaning only data from participants who followed the protocol throughout the study are included. A parallel Intention to Treat (ITT) analysis that considers the treatment received by all participants, without regard to protocol adherence yielded very similar results.

The vaccination regimen calls for two doses (3.75 microgram of antigen in combination with GSK’s pandemic adjuvant) given intramuscularly 21 days apart. The vaccine is stored at 2 °C to 8 °C, enabling the use of traditional vaccine supply and cold chain channels.

About Medicago

Medicago is on a mission to improve global public health using the power of plants. Founded in 1999 with the belief that innovative approaches and rigorous research would bring new solutions in healthcare, Medicago is a pioneer in plant-based therapeutics. We are proudly rooted in Quebec, with manufacturing capacity in both Canada and the US. Our passionate and curious team of over 500 scientific experts and employees are dedicated to using our technology to provide rapid responses to emerging global health challenges, and to advancing therapeutics against life-threatening diseases worldwide. Medicago is an affiliated company of Mitsubishi Tanabe Pharma Corporation.

For more information: www.medicago.com

About GSK and its commitment to tackling COVID-19

GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit www.gsk.com/about-us.

GSK is collaborating with companies and research groups across the world working on promising COVID-19 vaccine candidates through the use of our innovative vaccine adjuvant technology. The use of an adjuvant is of particular importance in a pandemic situation since it may reduce the amount of vaccine protein required per dose, allowing more vaccine doses to be produced and therefore contributing to protecting more people. GSK does not expect to profit from COVID-19 vaccines during the pandemic phase and will invest any short-term profit in coronavirus related research and long-term pandemic preparedness, either through GSK internal investments or with external partners.

About Mitsubishi Tanabe Pharma Corporation

Mitsubishi Tanabe Pharma Corporation (MTPC) Group, the majority parent company of Medicago, is one of the large Japanese pharmaceutical companies, with its headquarters in Osaka, Japan. It positions vaccines as one of its key R&D areas under its Medium-Term Management Plan 21-25 and is also working to develop new modalities of vaccines. MTPC Group will further contribute to the prevention of infectious diseases which is one of the world’s important social issues, by delivering a new option of plant-based VLP vaccine as a new type of vaccine. For further information please visit https://www.mt-pharma.co.jp/e/.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Medicago media contact (English):
Tanvir Janmohamed (North America)
+1 613 404 3611 (Toronto)
media.en@medicago.com

Gabby Koumis (UK/Global)
+44 (0) 78 3328 6784 (London)
media.en@medicago.com

GSK enquiries:
Media enquiries:

Simon Moore +44 (0) 20 8047 5502 (London)
Kathleen Quinn +1 202 603 5003 (Washington DC)

Analyst/Investor enquiries:

James Dodwell +44 (0) 20 8047 2406 (London)
Jeff McLaughlin +1 215 751 7002 (Philadelphia)

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Staffmark Group Leverages Rimini Street Support for Oracle PeopleSoft Powering Payroll for 35,000 Employees a Week26.1.2022 17:00:00 EET | Press release

Rimini Street, Inc. (NASDAQ: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced that Staffmark Group, an award-winning staffing and recruitment firm, continues to leverage Rimini Street to support the company’s PeopleSoft system environment support and maintenance. Since making the switch to Rimini Street, Staffmark has significantly improved the quality, responsiveness and depth of PeopleSoft support available to its internal IT team, enabled faster tax, legal and regulatory updates, and plans to reinvest support cost savings in service offering innovation and enhancements such as AI analysis capabilities and automated job posting functionality for employers and jobseekers – a vital part of its competitive market strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220126005280/en/

Covetrus Taps César França as President, Global Proprietary Brands26.1.2022 17:00:00 EET | Press release

Covetrus® (NASDAQ: CVET), a global leader in animal-health technology and services, today announced the appointment of César França as President, Global Proprietary Brands. França will lead the companywide development and management of Covetrus’ global proprietary brand portfolio, including the current Covetrus, Kruuse, Vi, Roadrunner Pharmacy, and Calibra brands. The company will rely on his vision and expertise to develop categories, build strategic partnerships, and identify external growth opportunities. França brings more than 25 years of leadership and experience in brand development and management, marketing, sales, business development, and general management to Covetrus. “We’re delighted to welcome César to this new and dynamic role,” said Matt Malenfant, Chief Commercial Officer at Covetrus. “César is a positive, trusted leader with a foundational belief in the power of people and brands. He will work closely with our commercial and operations teams to ensure effectiveness an

o9 Solutions Raises $295 Million From Strategic Investors to Continue its Growth Across Industry Verticals & Markets26.1.2022 16:00:00 EET | Press release

o9 Solutions, a leading enterprise AI software platform provider for transforming planning and decision-making speed and quality in companies across industry verticals, today announced that it has received equity investments totaling $295 million from General Atlantic, including BeyondNetZero, its climate investing venture, Generation Investment Management, a pure-play sustainability investment manager, and existing investor KKR. This significant investment will help o9 build on its momentum and accelerate growth for its AI-powered Integrated Business Planning platform it calls the “Digital Brain” across industry verticals and markets. It will also help o9 drive continued innovation in R&D, industry knowledge models and partner ecosystem development that will help companies implement o9’s game-changing platform faster and realize greater value. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220126005218/en/ Chakri Gottemukka

Tinubu Square Appoints Aurelien Pelletier as Chief Product & Technology Officer26.1.2022 16:00:00 EET | Press release

Tinubu Square, a proven SaaS solutions editor and a leader in enabling Credit Insurance & Surety digital transformation, is expanding. To sustain its current growth, Tinubu recently made acquisitions, onboarded new technologies and is equipping itself with the capabilities to achieve its ambitions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220126005498/en/ Tinubu Square - Aurelien PELLETIER - CPTO This is reflected in the investments made in its products, but also in the evolution of its organization, such as the arrival of Aurélien Pelletier as Chief Product & Technology Officer, a recognized specialist in cutting-edge digital technology. His role will be to accelerate Tinubu’s progression as a high-performance "software factory" and drive its products' evolution toward an end-to-end technological platform, a "Digital Highway" for our Credit Insurance & Surety customers connecting their entire ecosystem. Tinubu’s endea

Mattel and Disney Announce Multi-Year Global Licensing Agreement for Disney Princess and Disney Frozen Franchises26.1.2022 15:30:00 EET | Press release

Mattel, Inc. (NASDAQ: MAT) today announced a multi-year global licensing agreement for the Disney Princess and Frozen franchises. Mattel will have the global licensing rights to develop lines of toys for Disney Consumer Products, Games and Publishing, including fashion dolls, small dolls, and figures. The collection is expected to launch at retailers around the globe at the beginning of 2023. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220126005398/en/ (Graphic: Business Wire) “We are incredibly proud to welcome back the Disney Princess and Frozen lines to Mattel,” said Richard Dickson, President and Chief Operating Officer, Mattel. “As the worldwide leader in dolls, we look forward to bringing our unique Mattel Playbook approach to brand management, product and marketing expertise, and unrelenting attention to detail and quality to create innovative and inspiring lines for these iconic stories and characters.” The new li

Aceto Consolidates Acquisition of Six Manufacturers, Strengthening Its Unique Hybrid Model that Provides Major Supply Chain Benefits to Customers26.1.2022 15:30:00 EET | Press release

Aceto, a leading global provider of specialty materials for life sciences and advanced technology end markets, today reported it has consolidated and integrated its six manufacturing-related acquisitions to achieve a hybrid manufacturing/distribution model providing key benefits to its customers in high-growth end markets including pharmaceuticals, biopharmaceuticals, vaccines, nutraceuticals, agriculture, cosmetics and specialty chemicals. These developments are especially timely as the Covid-19 pandemic continues to show the fragility of global supply chains, requiring companies to rethink their current strategies and focus on achieving supply chain resilience and security. “Over seven decades, Aceto built a leading position as a value-added global ingredients supplier sourcing thousands of specialty ingredients to customers demanding quality and reliability,” said Gilles Cottier, Chief Executive Officer of Aceto. “In the past few years, we have moved aggressively to complement and e

PMI Included in 2022 Bloomberg Gender-Equality Index for Second Year Running26.1.2022 15:03:00 EET | Press release

Philip Morris International Inc. (PMI) (NYSE: PM) today announced that it has been included in the 2022 Bloomberg Gender-Equality Index (GEI) for the second year running, when the threshold for inclusion—based on both disclosure and data performance—has grown. This is in recognition of the significant progress PMI has made in increasing gender equality globally. Currently, 39.2% of management positions are held by women, an increase of more than 10% since 2014 and still growing. Silke Muenster, Chief Diversity Officer at PMI, noted: “I am delighted that PMI has made the GEI for the second year running, particularly given that the threshold for inclusion within this index has grown since last year. While we still have a long way to go, I am very proud of the progress we have made to date, and I am confident about achieving more in the future.” The business case for gender equality is clear: Companies in which woman hold more management roles, generate higher cash flow returns on investm

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom